Clinical Trials
240 trialsTivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
VOTRAGE
Institut Claudius Regaud
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
TSARINE
Centre Oscar Lambret
PRAMECE
Centre Oscar Lambret
SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases
British Columbia Cancer Agency
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
PRIMING
Royal Marsden NHS Foundation Trust
TOPOLOGY
Institut Curie
POP-ART
Institut Curie
GENTleMEN
University of Washington
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
M.D. Anderson Cancer Center
IRRADIATE-Lung
NYU Langone Health
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
University of California, San Diego
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
IL-2 PET Imaging in Advanced Solid Tumours
University Medical Center Groningen
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
M.D. Anderson Cancer Center
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Indiana University
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Fred Hutchinson Cancer Center
PREPARE
AIO-Studien-gGmbH
Using Imaging Data and Genomic Data to Predict Metastasis of Breast Cancer After Treatment
Chinese University of Hong Kong
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
IMMUNOSABR2
Maastricht University Medical Center
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
Indiana University
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Albert Einstein College of Medicine
LUTON
Hospices Civils de Lyon
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
ERICA
University of Michigan Rogel Cancer Center
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
University of Wisconsin, Madison
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
PIL
Augusta University
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
Yale University
CLQ
Instituto Nacional de Cancerologia de Mexico
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
ENSIGN
The Methodist Hospital Research Institute
OASIS
Georgetown University
Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients
University of Nebraska
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
M.D. Anderson Cancer Center
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
Albert Einstein College of Medicine
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
Metastatic Colorectal Cancer: Treatment Response With Dynamic Contrast MRI
American College of Radiology